MIRA INFORM
REPORT
|
Report Date : |
16.04.2012 |
IDENTIFICATION DETAILS
|
Correct Name : |
DR.LAZAR Y CIA.S.A. QUIMICA E INDUSTRIAL |
|
|
|
|
Registered Office : |
Ayacucho 318, Ciudad de Buenos Aires |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
26.12.1942 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Manufacture
& Commercialization of Medicinal Products for Human Use Pharmaceutical
Product |
|
|
|
|
No. of Employees
: |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
457,333 USD |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment
Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Argentina |
b1 |
b1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Registered Name
DR.LAZAR Y CIA.S.A. QUIMICA E INDUSTRIAL
CUIT.: 30-50119062-0
Summary
INCORPORATED IN
1942. BEGINNER OF ACTIVITIES. BALANCE AS OF 31/12/2010 (LAST KNOW). IT DOESN´T
REGISTER NEGATIVE ANTECEDENTS. FIT FOR CREDITS WITH GUARANTEES.
Operations
MEDICINAL PRODUCTS FOR
HUMAN USE
PHARMACEUTICAL PRODUTS
MANUFACTURE
COMMERCIALIZATION
Legal
Structure
Business type:
Limited Company
Incorporated: 26/12/1942
Registered: 18/03/1943
Duration: 99 years
End of fiscal year: 31/12
Contact
Dr.Alejandro Goya
(Administrative Management).
Legal Address: Ayacucho 318, Ciudad de Buenos Aires, República Argentina.
Headquarters: Velez Sarsfield 5855, Munro, Provincia de Buenos Aires, República
Argentina.
phone/fax: (54-11) 5550-2900
E-mail: aegoya@lazar.com.ar
Partners
President:
ZIFFER
ANDRES DANIEL
Vicepresident: SUARDI
LUIS MARIA
Director: WAISSMANN DE REWALD MARGARITA
Alternate Director: ZIFFER
ELENA RUTH
The president and v.president are in charge of the direction and administration
of the company and, as Managers, have use of signature indistinctly.
Corporate
Stock
The share capital is
established in $ 2.412.700 suscribed and paid in from which 99,73% is
contributed by the parent company:
FAGLU S.A.C.I.F.I.
Ayacucho 318, Ciudad de Buenos Aires.
Personal
Information
ZIFFER ANDRES DANIEL:
Argentinean, married in second time with Ana María Garzelli, Business
Administration, Born in 29/10/1959, DNI.No. 13.512.089 (CUIT No.20-13512089-9)
Address at Pte.Roca 353, Beccar, Pcia.de Buenos Aires.
He registers antecedents in the following companies:
> HEDAZI S.A.
President
> LOS LUPINES S.A.
President
> FARMALINK S.A.
Director
> FAGLU S.A.
Director
> LA CARLOTA S.A.
Director
> UNION CIENTIFICA BELGO ARGENTINA SA. Vicepresident
SUARDI LUIS MARIA:
Argentinean, married, born in 30/03/1933, Lawyer Dr. , LE.No. 4.097.661 (CUIT
No.20-040661-3) address at Pedro Moran 3510, Cdad.de Buenos Aires.
He registers antecedents in the following companies:
> FAGLU S.A.
President
> GRISSE COMPANY S.A. Alternate Director
> BENVENUTO S.A.C.I.
Trustee
History
While the incumbent
directors are rare in the particular details, being for information before
nuestor power, states that in order to address the representation of products
imported by mid-1934 the firm was constituted LABORATORIES LAZAR SH , whose
power lasted until the end of 1942.
At that time, by mutual agreement between the parties concerned, arises as to
continue the business under review and that, for the purposes provided it is
established in the directions that opportunity.
Economic-Financial Position
The leaders of the
society and other opportunities have declined to provide information as strict
accounting.
Of the inquiries made through third parties, we obtain the following figures
from the balance to close the December 31, 2010, the last of which are known to
date.
ACTIVE
------
CURRENT .................. $ 60,372,680
CURRENT .................. $ 9,928,064
____________
$ 70,300,744
============
LIABILITIES
-----------
CURRENT .................. $ 26,496,815
CURRENT .................. $ 3,640,972
____________
$ 30,137,787
EQUITY ................... $ 40,162,957
____________
$ 70,300,744
============
NET SALES ................ $ 120,326,325
COST OF SALES ............ $ 63,478,233
GROSS INCOME ............. $ 56,848,092
FINAL INCOME ............. $ 4,278,304
============
The above figures show a solid financial-economic structure, so the
relationship between commitments and equity that are clustered in equity and
current asset values, taken from normal realization in the short to medium
term.
Commercial operations for the period reached significance amounts of good sales
surpassing by 20.6% at the immediately preceding fiscal year, with a discreet
return, although higher than the previous period by 25.3%.
The actions of the company until peresente shows no adverse alternatives and
assigned stable outlook.
Of the amounts that have been mentioned above, have been able to extract the
following indices:
WORKING CAPITAL $ 33,875,865
CURRENT LIQUIDITY 2.28
DEBT 0.75
SOLVENCY 1.33
2.33 TOTAL SOLVENCY
S PROFIT / SALES 3.6%
Assets
REAL ESTATE:
---------
Avda.Velez Sarsfield 5855, Carapachay, Prov.de Buenos Aires, OF INTERESTING
MARKET VALUE.
VEHICLES:
-------
7 MOVIL UNITS DEDICATED TO ITS OPERATIONS Volvo, Volkswagen, Peugeot, Fiat AND
Iveco. NO MORE DETAILS AVAILABLE.
NO DOCUMENTATION IS AVAILABLE TO VERIFY IF THE ASSETS ARE FREE OF BURDENS.
Commercial
References Consulted
> PLASTINORT S.A.
> IMPREFIN S.A.
> HERTWELL S.A.
> BELSTORE
The company owner maintains relationship with these suppliers for several years
and part of it gets credit for the purchase of various inputs that are
necessary for its operation, which uses as its operating needs so require it.
At present meets the obligations in terms classified as normal and is well
referenced.
The credits granted are granted on terms not exceeding 60 days.
Evolution
and Results
Company renowned and
important in its sector, has to do with laboratory equipped with modern
technology, according to the demands of a highly competitive market, in whose
care managers are responsible together with the necessary staff.
Throughout its history the company grew to support the pharmaceutical and
clinical research to the development and synthesis of new molecules, constantly
adding new products to its line and providing invaluable therapeutic elements
in the fight against the most diverse conditions.
With a past of hierarchy and a modern present, the company currently has an
industrial model, which makes synthesis of drugs for own production, for export
and for third parties with which rersponden processing areas to the most
advanced and demanding standards international quality standards.
Numerous of own brand products elaboration, among which may be mentioned the
following:
ADIUVAN MET NOVURIT
DERMOTOPIC SIMULTAN A
REGULACID RESTINIL
RIFAMPICINA SUPLIGOL NF
TALIDO9MIDA LAZAR TOMOXIFENO
LAZAR
TEURIPAR XICLOVIR
NEUROLAZ PARATROPINA
PARACETAMOL LAZAR
RANITIDINA LAZAR
FLOGISILIN GLUKENIL
LACTULON LIPONORM
MEDOBIS CIPROFLOXACINA LAZAR
DILUTOL FANALETAS
ALFADIMAN ARZIMOL
FOREIGN TRADING:
----------------
In the last 12 months of management has made ??imports for $ s 3,176,927 from
the following countries:
UNITED ARAB 602,841
URUGUAY 505,371
South Africa 400,780
OTHER 1,667,934
The main imports were:
Heterocyclic compounds.
Chemically pure sugars.
Aluminum Sheet and Strip laboratory.
Payment
Record and Credit Risk
BANCO DE LA
PROV.DE BS.AS.
BANCO DE LA NACION
BANCO DE GALICIA Y BS.AS.
BBVA BANCO FRANCES
INSURANCES:
-----------
ZURICH CIA.DE SEGUROS S.A.
CREDIT RISK:
------------
01/2012
BANCO SANTANDER $ 1.955.300 1
FRANCES 161.800
1
GALICIA
91.200 1
PROV. DE B.A. 500
1
AMERICAN EXPRESS 58.000
1
Situation 1: normal.
Concept
At present there is no
record of any indole negative that may affect our business concept of informed
and determined through the checks that maintains proper conduct in the care of
general obligations assumed.
* NO OBJECTIONS.
Final
Opinion
This society is
considered suitable for current economic importance credits in the conditions
of the field.
* SUITABLE FOR CREDITS.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.51.42 |
|
UK Pound |
1 |
Rs.81.93 |
|
Euro |
1 |
Rs.67.67 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.